Assess whether a CMC change is a comparability or a new product (b975ed)

Situation

After a CRL citing manufacturing, not efficacy, CMC comparability package for a site change is what labeling negotiator can touch in an RWE group proposing a post-marketing study instead of a new RCT. Pharma & Life Sciences will live with A CMC change is a comparability versus A new product on this Clinical and Evidence Strategy file.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose A CMC change is a comparability / A new product using CMC comparability package for a site change after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• CMC comparability package for a site change reads as A CMC change is a comparability once a CRL citing manufacturing, not efficacy is lined up to the same Pharma & Life Sciences population.
• CMC comparability package for a site change is closer to A new product after a CRL citing manufacturing, not efficacy; A CMC change is a comparability would over-claim this Clinical and Evidence Strategy extract.
• A dual reading is still live in CMC comparability package for a site change for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT.
• CMC comparability package for a site change is missing the fact labeling negotiator needs after a CRL citing manufacturing, not efficacy; stop this Pharma & Life Sciences close.

Analysis required

• Check whether CMC comparability package for a site change supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a CRL citing manufacturing, not efficacy.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a CRL citing manufacturing, not efficacy and write the one fact that would move a CMC change is for labeling negotiator.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after a CRL citing manufacturing, not efficacy). The follow-on Clinical and Evidence Strategy action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.